Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Copanlisib + ERAS-007 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Copanlisib | Aliqopa | BAY80-6946|BAY806946 | PIK3CA inhibitor 24 PIK3CD inhibitor 27 | Aliqopa (copanlisib) is a selective PIK3CA and PIK3CD inhibitor that prevents activation of Akt, resulting in inhibition of cell cycle progression and increased apoptosis (PMID: 24013662, PMID: 25528022). Aliqopa (copanlisib) is FDA approved for adult patients with follicular lymphoma (FDA.gov). |
ERAS-007 | ASN007|ASN-007|ASN 007|ERAS007|ERAS 007 | ERK Inhibitor (pan) 21 | ERAS-007 (ASN007) is a small molecule that inhibits ERK1/2, which may result in decreased tumor cell proliferation and reduced tumor growth (PMID: 34337566). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
NRAS G13D | mantle cell lymphoma | sensitive | Copanlisib + ERAS-007 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, the combination of ERAS-007 (ASN007) and Aliqopa (copanlisib) inhibited tumor growth in a cell line xenograft model of mantle cell lymphoma harboring NRAS G13D, and demonstrated improved efficacy over either agent alone (PMID: 34337566). | 34337566 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|